ELTX (STOCKS)
Elicio Therapeutics, Inc. Common Stock
$8.400000
-0.300000 (-3.45%)
Prev close: $8.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert T. Connelly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $153.44M
- Employees
- 26
- P/E (TTM)
- -2.47
- P/B (TTM)
- 37.99
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $42.35M |
| Nonoperating Income/Loss | -$3.51M |
| Research and Development | $30.53M |
| Operating Income/Loss | -$42.35M |
| Income/Loss From Continuing Operations After Tax | -$45.86M |
| Income/Loss From Continuing Operations Before Tax | -$42.35M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$45.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$45.86M |
| Net Income/Loss Available To Common Stockholders, Basic | -$45.86M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.11 |
| Diluted Earnings Per Share | -$3.11 |
| Basic Average Shares | 15,730,333 |
| Diluted Average Shares | 15,730,333 |
| Assets | $28.28M |
| Current Assets | $21.47M |
| Noncurrent Assets | $6.82M |
| Fixed Assets | $328.00K |
| Other Non-current Assets | $6.49M |
| Liabilities | $24.47M |
| Current Liabilities | $6.52M |
| Accounts Payable | $321.00K |
| Wages | $1.69M |
| Other Current Liabilities | $4.51M |
| Noncurrent Liabilities | $17.95M |
| Equity | $3.82M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.82M |
| Liabilities And Equity | $28.28M |
| Net Cash Flow From Operating Activities | -$38.90M |
| Net Cash Flow From Operating Activities, Continuing | -$38.90M |
| Net Cash Flow From Investing Activities | -$1.87M |
| Net Cash Flow From Investing Activities, Continuing | -$1.72M |
| Net Cash Flow From Financing Activities | $32.06M |
| Net Cash Flow From Financing Activities, Continuing | $32.06M |
| Exchange Gains/Losses | $171.00K |
| Net Cash Flow | -$8.68M |
| Net Cash Flow, Continuing | -$8.85M |
| Comprehensive Income/Loss | -$45.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$45.69M |
| Other Comprehensive Income/Loss | -$45.69M |